CellaVision AB (publ) (CEVI) Earnings Call Transcripts

CellaVision AB (publ)'s Latest Earnings Call - Q1 FY2026

CellaVision AB reported a challenging Q1 2026, with net sales of SEK 166 million, down 14.6% year-over-year, primarily due to a significant inventory adjustment in the EMEA region. EBITDA was SEK 40 million, representing a margin of 24%. Management indicated that while the inventory issues impacted current performance, they expect to see improved sales in Q2 and positive contributions from new product launches in the latter half of 2026.

Reported metrics

Guidance from management

Management expects improved sales in Q2 2026, with no negative growth anticipated in instrument sales. They are optimistic about contributions from new product launches in the latter half of the year.

What management said

Yes. Thanks, Simon. I think when it took place -- so you can say we were informed in this quarter. So I think the increase is probably throughout last year when there were ERP implementations. That's kind of how we understand the situation. And we believe that the majority of the stocking is probably digested throughout this quarter. but there may be somewhat of a spillover of a little bit stock left in the subsequen...

No, I think what we hear is that, in general, and I think we all know that there is a debate in all countries around investments into the defense, and that is driving a little bit of pressure also on the health care side. So that's what we also -- when we discuss this with our partner with certain countries, it's not all countries, but there are countries -- as an example, the U.K. where there appears to be a little ...

What analysts pressed on

Analysts expressed concerns regarding the prolonged inventory adjustments in EMEA and the potential impact on future sales. There were also questions about the sustainability of growth in the Americas and the effects of public healthcare budget constraints on demand.

Main topics on the call

• EMEA Inventory Adjustment — CellaVision experienced a substantial 32% decline in sales in EMEA, attributed to 'inventory adjustments with our main distribution partner.' Management noted that this was a temporary situation and not reflective of und...
• Strong Performance in Americas — The Americas region showed resilience with a 13% organic growth rate, despite currency headwinds. Management emphasized 'continued strong adoption of our integrated large instruments' in the U.S.
• New Product Launches — CellaVision launched the Bone Marrow Aspirate application and a significant software upgrade, which management expects to contribute to revenue in the second half of 2026. They stated, 'we expect to see a funnel being bu...
• Cash Flow and Financial Health — The company reported positive operating cash flow of SEK 62 million and maintained a strong cash position with SEK 230 million on the balance sheet. This reflects ongoing financial stability despite the current sales cha...

Read the full CellaVision AB (publ) transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 26 CellaVision AB (publ) earnings call transcripts on record, spanning February 5, 2020 to July 17, 2026. Based on this history, CellaVision AB (publ) reports quarterly. The most recent call on file is dated July 17, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

CEVI

Exchange

OM

Country

SE

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

26

First call

February 5, 2020

Most recent

July 17, 2026

Reporting cadence

quarterly